Novartis’ Scemblix Approved by NMPA for Newly Diagnosed Ph+ CML-CP Patients
Swiss pharmaceutical company Novartis (NYSE: NVS) announced that it has received marketing approval from China’s...
NYSE: NVS
Novartis’ Kisqali Receives NMPA Approval for High-Risk Early Breast Cancer
Switzerland-based Novartis (NYSE: NVS) announced this week that it has received another indication approval from...
Novartis to Acquire Regulus Therapeutics for Up to $1.7 Billion
Swiss pharmaceutical giant Novartis (NYSE: NVS) is set to acquire U.S.-based Regulus Therapeutics Inc. (NASDAQ:...
Novartis Q1 2025 Results: Net Sales Up 15% YOY, Strong Growth in Key Brands
Swiss pharmaceutical giant Novartis (NYSE: NVS) released its Q1 2025 financial report, showing net sales...
Novartis Announces USD 23 Billion Investment to Expand U.S. Manufacturing and R&D Hubs
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced plans to invest USD 23 billion over...
Novartis’ Vanrafia Gets FDA Accelerated Approval for IgAN
Switzerland-based Novartis (NYSE: NVS) announced that it has received accelerated approval from the US Food...
Novartis’ Fabhalta Approved in China for C3 Glomerulopathy
Novartis’ (NYSE: NVS) Fabhalta (iptacopan) has received approval from China’s National Medical Products Administration (NMPA)...
Novartis’ Pluvicto Gains Expanded FDA Approval for Prostate Cancer Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received expanded indication approval from...
Novartis’ Fabhalta Approved by FDA for C3 Glomerulopathy Treatment
Swiss pharmaceutical giant Novartis’ (NYSE: NVS) iptacopan, marketed as Fabhalta, has received approval from the...
Novartis’ Cosentyx Approved by NMPA for Moderate to Severe Hidradenitis Suppurativa
Swiss giant Novartis’ (NYSE: NVS) Cosentyx (secukinumab) has secured another indication approval from China’s National...
Kyorin Pharmaceutical Licenses KRP-M223 to Novartis for Global Development
Japan-based Kyorin Pharmaceutical Co., Ltd. announced a licensing agreement with Novartis (NYSE: NVS), granting the...
Novartis to Acquire Anthos Therapeutics for $3.1B, Boosting Factor XI Inhibitor Portfolio
Swiss pharma giant Novartis (NYSE: NVS) announced plans to acquire Anthos Therapeutics, Inc., a cardiometabolic-focused...
Bio-Thera’s Biosimilars BAT2306 and BAT2506 Accepted for Review by NMPA and EMA
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that the market filings for its biosimilars BAT2306...
Novartis to Defend Entresto Patent After CAFC Ruling
Novartis (NYSE: NVS) has revealed a favorable decision by the US Court of Appeals for...
Novartis Announces Positive Results from Phase III STEER Study on SMA Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive topline results from the Phase III...
BioAge Labs and Novartis Partner to Discover Aging-Related Therapeutic Targets
US-based BioAge Labs, Inc. has announced a strategic research partnership with Swiss pharmaceutical giant Novartis...
UCB’s Minzasolmin Fails to Meet Endpoints in ORCHESTRA Study for Early Parkinson’s
Belgium-based biopharmaceutical company UCB (EBR: UCB) has announced the disappointing results of the ORCHESTRA proof-of-concept...
Siemens Healthineers AG Acquires Advanced Accelerator Applications to Boost PETNET Solutions
Germany-based Siemens Healthineers AG (ETR: SHL) has announced the completion of its acquisition of Advanced...
Novartis’ Kisqali Shows Sustained Efficacy in NATALEE Study at SABCS 2024
Swiss pharmaceutical giant Novartis (NYSE: NVS) presented updated results from the pivotal Phase III NATALEE...
Novartis’ Fabhalta Demonstrates Positive Results in APPULSE-PNH Phase IIIb Study
Swiss pharmaceutical major Novartis (NYSE: NVS) has released positive topline results from the APPULSE-PNH Phase...